Here are relevant reports on : recombinant-therapies-advanced-technologies-and-global-market
-
Recombinant Proteins Market by Product (Growth Factors, Chemokines, Structural Proteins, Membrane Proteins), Application (Drug Discovery & Development (Biologics, Vaccines, Cell & Gene Therapy), Research, Biopharma Production) & Region - Global Forecast to 2028
The global recombinant proteins market, valued at US$2.1 billion in 2022, stood at US$2.2 billion in 2023 and is projected to advance at a resilient CAGR of 7.2% from 2023 to 2028, culminating in a forecasted valuation of US$3.2 billion by the end of the period. Growth in the market can be attributed to factors such as rising incidence of chronic diseases, growing demand for biologics and biosimilars due to expiration of patents, rising demand for customized medicine and increasing government initiatives for R&D in life sciences research.
- Published: January 2024
- Price: $ 4950
- TOC Available:
-
Bleeding Disorders Treatment Market by Type (Hemophilia A, Hemophilia B, vWD), Drug Class (Plasma Derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Desmopressin, Antibrinolytics, Fibrin Sealant) - Global Forecast to 2021
The global bleeding disorders treatment market size is projected to grow at a CAGR of 7.9%. The major factors driving the market growth include the growing patient population base, R&D activities, and increasing focus on recombinant products by pharmaceutical companies. Emerging markets offer significant growth opportunities for the bleeding disorders treatment market.
- Published: July 2016
- Price: $ 4950
- TOC Available:
-
Hemophilia Treatment Market by Indication (Type A, Type B), Therapy (Replacement (Recombinant, Plasma Derived), Route of Administration, End User - Global Forecast to 2027
The global hemophilia treatment market is projected to reach USD ~15 billion by 2027 from USD 12 Billion in 2022, at a CAGR of 5% during the forecast period. The major players in the global hemophilia market are Bayer Healthcare (Germany), Octapharma AG (Switzerland), Novo Nordisk (Denmark), Kedrion (Italy), Pfizer Inc. (US), Biogen (US) among others.
- Published: March 2026
- Price: $ 4950
- TOC Available:
-
Vaccines Market by Technology (Conjugate, Recombinant, Inactivated, Live Attenuated, Viral Vector, mRNA), Type (Monovalent, Multivalent), Disease (Pneumococcal, Flu, Hepatitis, MMR, RSV), Route of Administration (IM, SC, Oral)-Global Forecast to 2030
The global vaccines market, valued at US$59.52 billion in 2024, stood at US$50.46 billion in 2025 and is projected to advance at a resilient CAGR of 4.8% from 2025 to 2030, culminating in a forecasted valuation of US$63.66 billion by the end of the period.
- Published: September 2025
- Price: $ 4950
- TOC Available:
-
Cancer Vaccines Market by Type (Preventive, Therapeutic (Neoantigen)), Technology (Cell-based Vaccine, Recombinant), Indication (Cervical, Prostate), ROA (Intramuscular, Intravenous), End User (Hospitals, Speciality Clinics) - Global Forecast to 2032
The global cancer vaccines market, valued at US$9.70 billion in 2023, stood at US$9.84 billion in 2024 and is projected to advance at a resilient CAGR of 5.4% from 2024 to 2032, culminating in a forecasted valuation of US$15.00 billion by the end of the period. The cancer vaccines market is growing rapidly, fueled by rising prevalence of cancer, technological advancements in immunotherapy, and increasing adoption of preventive healthcare across the globe.
- Published: December 2024
- Price: $ 4950
- TOC Available:
-
North America Vaccines Market by Technology (Conjugate, Recombinant, Inactivated, Live Attenuated, Viral Vector), Type (Monovalent, Multivalent), Disease (Pneumococcal, Flu, Hepatitis, MMR), Route of Administration (IM, SC, Oral)- Global Forecast to 2030
The North America vaccines market, valued at US$25.95 billion in 2024, stood at US$25.29 billion in 2025 and is projected to advance at a resilient CAGR of 7.1% from 2025 to 2030, culminating in a forecasted valuation of US$35.68 billion by the end of the period. The vaccines market is growing rapidly, driven by swift global vaccine development and commercialization, higher rates of infectious diseases necessitating preventive vaccines, expanded immunization initiatives, innovations in vaccine technology, and increased government funding and investments for novel vaccines against diverse diseases.
- Published: March 2026
- Price: $ 4950
- TOC Available:
-
Global Albumin Market, by Product (Human Serum Albumin, Bovine Albumin, Recombinant Serum Albumin) by Application (Therapeutic, Drug Delivery, Culture Media, Vaccine Ingredient) by Region - Forecast to 2022
The global albumin market is projected to grow at a CAGR of around 6% during the forecast period (2017-2022). Factors such as the high demand of albumin in R&D activities, rising non-therapeutic application of albumin, development of plant based albumin, rising production of immunoglobulins, and rise in plasma collection are driving the market. However, the stringent regulations, limited reimbursement, and irrational uses and adverse effects associated with albumin are the factors restraining the growth of this market.
- Published: March 2026
- Price: $ 4950
- TOC Available:
-
Europe Vaccines Market by Technology (Conjugate, Recombinant, Inactivated, Live Attenuated, Viral Vector, mRNA), Type (Monovalent, Multivalent), Disease (Pneumococcal, Flu, Hepatitis, MMR, RSV), Route of Administration (IM, SC, Oral) - Forecast to 2030
The Europe vaccines market, valued at US$10.53 billion in 2024, stood at US$9.97 billion in 2025 and is projected to advance at a resilient CAGR of 6.6% from 2025 to 2030, culminating in a forecasted valuation of US$13.74 billion by the end of the period. The vaccines market is growing due to fast global developments and the commercialization of vaccines, rising rates of infectious diseases, which require preventive measures, and government initiatives to encourage vaccinations, immunization programs, advancements, and investments in new vaccines against various diseases.
- Published: March 2026
- Price: $ 4950
- TOC Available:
-
Respiratory Syncytial Virus (RSV) Vaccines Market by Technology (Recombinant, Inactivated & Subunit, Others), Type (Monovalent, Multivalent), End User (Pediatric, Adult) & Region – Global Forecast to 2030
The global Respiratory Syncytial Virus (RSV) Vaccines market, valued at US$1.53 billion in 2024, stood at US$1.60 billion in 2025 and is projected to advance at a resilient CAGR of -4.9% from 2025 to 2030, culminating in a forecasted valuation of US$1.24 billion by the end of the period. Growth is driven by the high burden of RSV among infants and older adults.
- Published: March 2026
- Price: $ 4950
- TOC Available:
-
Advanced Energy Recovery System Market - By Type, Technology & Geography (2014-2019)
- Published: March 2026
- Price: $ 4950
- TOC Available:
Records 21 to 30 of 50
